In case you missed it, a new report from health policy researcher Alex Brill, founder and CEO of Matrix Global Advisors and former policy director and chief economist for the U.S. House Committee on Ways and Means, âRebates and Drug
A recent blog (âPayers and PBMs Profit from Obscure Pharmacy Fees, While Seniors See No Relief in Prescription Costsâ) suggests performance-based price concessions are retained by PBMs, restrict the growth of independent pharmacies, and inflate Medicare Part D enrolleeâs out-of-pocket costsâunfounded
The insulin market today is not the market of five years ago. The insulin market of the 2010s was defined by just three drug companies and their brand name products. The lack of competitors meant skyrocketing list prices, increasing once
(Washington, D.C.) â Today, representative organizations of Americaâs pharmaceutical supply and payment chain, including prescription and over-the-counter brand and generic manufacturers; wholesalers; retail, specialty, and managed care, pharmacies; health insurance providers and other payers; pharmacists in hospitals and health systems; and
Pharmacy benefit companies are strong proponents of a highly functioning biosimilar market. Bringing more biosimilars to market, over time, will allow PBMs to more effectively leverage competition to reduce drug costs for health plan sponsors and patients. As biosimilar competition
(Washington, D.C.) â The Pharmaceutical Supply and Payment Chain Coalition issued the following statement in response to the Administrationâs 100-day review of the actions needed to address vulnerabilities in our nationâs pharmaceutical supply chain and what measures need to be taken in order
As a reminder, the U.S. House of Representatives Committee on Oversight and Reform previously found, in a 2021Â report, that PBM-negotiated rebates are not correlated with the list prices set by drug companies. The report also finds that âdrug companies have
©2024 PCMA. All Rights Reserved.
